BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $124,713.42 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen A. Foster sold 3,414 shares of the stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $36.53, for a total value of $124,713.42. Following the transaction, the insider now owns 74,208 shares of the company’s stock, valued at $2,710,818.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

BLFS opened at $34.86 on Thursday. BioLife Solutions, Inc. has a 12-month low of $8.88 and a 12-month high of $47.97. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -47.75, a PEG ratio of 50.41 and a beta of 1.55. The business has a 50 day moving average of $37.99 and a 200-day moving average of $36.34.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Sunday, March 21st. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.04). BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%. The business had revenue of $14.73 million during the quarter, compared to analyst estimates of $13.43 million. As a group, analysts forecast that BioLife Solutions, Inc. will post 0.01 earnings per share for the current year.

A number of research firms recently issued reports on BLFS. Northland Securities increased their price objective on BioLife Solutions from $35.00 to $55.00 in a report on Monday, December 28th. Benchmark upgraded BioLife Solutions from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Monday, March 29th. KeyCorp raised their price target on BioLife Solutions from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 29th. Stephens raised their price target on BioLife Solutions from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Tuesday, March 23rd. Finally, Maxim Group raised their price target on BioLife Solutions from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, March 23rd. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $45.10.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Strs Ohio acquired a new stake in shares of BioLife Solutions in the fourth quarter valued at approximately $31,000. The Manufacturers Life Insurance Company lifted its position in shares of BioLife Solutions by 11.9% in the fourth quarter. The Manufacturers Life Insurance Company now owns 8,629 shares of the medical equipment provider’s stock valued at $344,000 after buying an additional 917 shares during the last quarter. Northern Trust Corp lifted its holdings in BioLife Solutions by 0.4% during the 4th quarter. Northern Trust Corp now owns 260,536 shares of the medical equipment provider’s stock worth $10,392,000 after purchasing an additional 1,121 shares during the last quarter. Morgan Stanley lifted its holdings in BioLife Solutions by 6.8% during the 3rd quarter. Morgan Stanley now owns 18,779 shares of the medical equipment provider’s stock worth $543,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Citigroup Inc. lifted its holdings in BioLife Solutions by 265.7% during the 4th quarter. Citigroup Inc. now owns 3,156 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 2,293 shares during the last quarter. 67.66% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Recommended Story: What are different types of coverage ratios?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.